Skip to main content

Table 3 Effects of K30, KL30 and K50 on body temperatures (Mean ± SD) measured in 6 dogs using crossover design

From: Serum concentration of ketamine and antinociceptive effects of ketamine and ketamine-lidocaine infusions in conscious dogs

 

K30

KL30

K50

Baseline

38.6 ± 0.4

38.7 ± 0.3

38.8 ± 0.2

20 min

39.0 ± 0.5a

39.1 ± 0.6a

39.2 ± 0.6a

40 min

39.1 ± 0.6a

39.0 ± 0.5a

39.3 ± 0.5a

60 min

39.2 ± 0.4a

39.1 ± 0.4a

39.3 ± 0.5a

90 min

39.2 ± 0.4a

39.1 ± 0.4a

39.0 ± 0.4a

120 min

39.1 ± 0.5a

39.1 ± 0.5a

39.0 ± 0.3a

140 min

39.3 ± 0.5a

39.2 ± 0.4a

39.0 ± 0.3

160 min

39.0 ± 0.4a

39.1 ± 0.5a

39.0 ± 0.3

  1. K30 Ketamine 0.5 mg/kg loading dose followed by 30 μg/kg/min CRI, KL30 Ketamine 0.5 mg/kg loading dose followed by 30 μg/kg/min and lidocaine hydrochloride 2 mg/kg loading dose followed by 100 μg/kg/min CRI, K50 0.5 mg/kg loading dose followed by 50 μg/kg/min CRI adenotes significant difference from baseline within same treatment. Overall significance was set at a value of P < 0.05